Please provide your email address to receive an email when new articles are posted on . Results showed two regimens — 120 mg/kg cyclophosphamide and 125 mg/m 2 fludarabine, or 60 mg/kg ...

HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related ...

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric ...

AFNT-211: An FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Outpatient Lymphodepletion Shows Comparable Safety and Efficacy: Patients receiving lymphodepletion in the outpatient setting, followed by Tecartus, had similar non-relapse mortality and safety ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Bendamustine lymphodepletion resulted in significant CAR T-cell expansion among patients with ...

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric ...

Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). This is an ASCO Meeting Abstract ...

This was a prospective pilot study that included 18 consecutive adult patients (7 males) treated in a single institution (CHU de Nantes, Nantes, France) between January 2008 and July 2010. The ...